Cerivastatin: A cellular and molecular drug for the future?

Cellular and Molecular Life Sciences

Volumn 60, Issue 1, 2003, Pages 144-164

  Siegel Axel, D I ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Atherosclerosis; Cerivastatin; HMG CoA reductase inhibitors; Isoprenoids; Pleiotropic effects

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVINOLIN; STATIN;

ALZHEIMER DISEASE; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD CELL; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; HUMAN; KINETICS; LIPOPHILICITY; NONHUMAN; ORGAN TRANSPLANTATION; OSSIFICATION; OSTEOPOROSIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; STEM CELL; THROMBOSIS; TUMOR GROWTH; UNITED STATES; VASCULAR TISSUE;

ANGIOTENSIN II; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; EXTRACELLULAR MATRIX; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PHYSIOLOGIC; PYRIDINES; RECEPTORS, ANGIOTENSIN; THROMBOSIS;

EID: 0037278559     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180300010     Document Type: Review

References (166)

1. Amarenco P. (2001) Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 57: S35-S44
2. Brown W. V. (2001) Therapies on the horizon for cholesterol reduction. Clin. Cardiol. 24: III24-III27
3. The Lovastatin Study Group II (1986) Therapeutic response to lovastatin (mevinolin) in nonfamilial hyper-cholesterolemia: a multicenter study. JAMA 256: 2829-2834
4. Endo A., Kuroda M. and Tanzawa K. (1976) Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72: 323-326
5. Endo A, Tsujita Y., Kuroda M. and Tanzawa K. (1977) Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-me-thylglutaryl-coenzyme A reductase. Eur. J. Biochem 77: 31-36
6. Goldstein J. L. and Brown M. S. (1990) Regulation of mevalonate pathway. Nature 343: 425-430
7. Alberts A. W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C. et al. (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77: 3957-3961
8. Endo A. (1992) The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33: 1569-1582
9. Hatanaka T. (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet. 39: 397-412
10. Igel M., Sudhop T. and Bergmann K. von (2001) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 57: 357-364
11. Hamelin B. A. and Turgeon J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19: 26-37
12. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R. and Bernini F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84: 413-428
13. Faggiotto A. and Paoletti R. (2000) Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins? Curr. Atheroscler. Rep. 2: 20-25
14. Isaacsohn J, Zirmy M., Mazzu A., Lettieri J, and Heller A. H. (2001) Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults. Eur. J. Clin. 56: 897-903
15. Cheng-Lai A. (2000) Cerivastatin. Heart Dis. 2: 93-99
16. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D. et al. (1997) Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 135: 119-130
17. Muck W. (2000) Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet. 39: 99-116
18. McClellan K. J., Wiseman L. R. and McTavish D. (1998) Cerivastatin. Drugs 55: 415-420
19. Blumenthal R. S. (2000) Statins: effective antiatherosclerotic therapy. Am. Heart J. 139: 577-583
20. Lea A. P. and McTavish D. (1997) Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53: 828-847
21. McTavish D. and Sorkin E. M. (1991) Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42: 65-89
22. Plosker G. L. and Wagstaff A. J. (1996) Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 51: 433-459
23. Plosker G. L. and McTavish D. (1995) Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 50: 334-363
24. Henwood J. M. and Heel R. C. (1988) Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36: 429-454
25. Plosker G. L., Dunn C. I. and Figgitt D. P. (2000) Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Drugs 60: 1179-1206
26. Stein E. A. (2001) New statins and new doses of older statins. Curr. Atheroscler. Rep. 3: 14-18
27. Betteridge D. J. (1999) International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group. Int. J. Clin. Pract. 53: 243-250
28. Insull W. J., Isaacsohn J., Kwiterovich P., Ra P., Brazg R., Dujovne C. et al. (2000) Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. J. Int. Med. Res. 28: 47-68
29. Stein E. (1998) Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Atherosclerosis 139 (suppl 1): S15-S22
30. Roberts W. C. (1997) The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. 80: 106-107
31. Stein E., Isaacsohn J., Stoltz R., Mazzu A., Liu M. C., Lane C. et al. (1999) Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. 83: 1433-1436
32. Isaacsohn J., Insull W. J., Stein E., Kwiterovich P., Patrick M. A., Brazg R. et al. (2001) Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin. Cardiol. 24: IV1-IV9
33. Dujovne C. A., Knopp R., Kwiterovich P., Hunninghake D., McBride T. A. and Poland M. (2000) Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group. Mayo Clin. Proc. 75: 1124-1132
34. McPherson R., Hanna K., Agro A. and Braeken A. (2001) Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness. Clin. Ther. 23: 1492-1507
35. Anonymous (1998) Cerivastatin for hypercholesterolemia. Med. Lett. Drugs Ther. 40: 13-14
36. Massy Z. A., Keane W. F. and Kasiske B. L. (1996) Inhibition of mevalonate pathway: benefits beyond cholesterol reduction? Lancet 347: 102-103
37. Massy Z. A. and Guijarro C. (2001) Statins: effects beyond cholesterol lowering. Nephrol. Dial. Transplant. 16: 1738-1741
38. Feleszko W., Mlynarczuk I. and Nowis D. (2001) In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. FEBS Lett. 503: 219-220
39. Denoyelle C., Vasse M., Korner M., Mishal Z., Ganne F., Vannier J. P. et al. (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148
40. Garrett I. R., Gutierrez G. and Mundy G. R. (2001) Statins and bone formation. Curr. Pharm. Des. 7: 715-736
41. Sugiyama T. and Kawai S. (2002) Changes in bone biochemical markers after high-dose cerivastatin treatment in a woman with osteogenesis imperfecta. J. Bone Miner. Metab. 19: 382-384
42. Brown M. S. and Goldstein J. L. (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21: 505-517
43. Brown M. S., Faust J. R. and Goldstein J. L. (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 253: 1121-1128
44. Takai Y., Sasaki T. and Matozaki T. (2001) Small GTP-binding proteins. Physiol. Rev. 81: 153-208
45. Thoma N. H., Iakovenko A., Goody R. S. and Alexandrov K. (2001) Phosphoisoprenoids modulate association of Rab geranylgeranyltransferase with REP-1. J. Biol. Chem. 276: 48637-48643
46. Wilson A. L., Erdman R. A., Castellano F. and Maltese W. A. (1998) Prenylation of Rab8 GTPase by type I and type II geranylgeranyl transferases. Biochem. J. 333: 497-504
47. Laezza C., Bucci C., Santillo M., Bruni C. B. and Bifulco M. (1998) Control of Rab5 and Rab7 expression by the isoprenoid pathway. Biochem. Biophys. Res. Commun. 248: 469-472
48. Laufs U. and Liao J. K. (2000) Targeting Rho in cardiovascular disease. Circ. Res. 87: 526-528
49. Ross R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-808
50. Lusis A. J. (2000) Atherosclerosis. Nature 407: 233-241
51. Duez H., Fruchart J. C. and Staels B. (2001) PPARS in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk 8: 187-194
52. Lee R. T. and Libby P. (1997) The unstable atheroma. Arterioscler. Thromb. Vasc. Biol. 17: 1859-1867
53. Galls Z. S. and Khatri J. J. (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90: 251-262
54. Ganne F., Vasse M., Beaudeux J. L., Peynet J., Francois A., Mishal Z. et al. (2000) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost. 84: 680-688
55. Kienast J., Padro T, Steins M., Li C. X., Schmid K. W., Hammel D. et al. (1998) Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb. Haemost. 79: 579-586
56. Ganne F., Vasse M., Beaudeux J. L., Peynet J., Francois A., Paysant J. et al. (1999) Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins - consequences for plasmin generation and monocyte adhesion. Thromb. Haemost. 81: 594-600
57. Waltenberger J. (2001) Pathophysiological bases of unstable coronary syndrome. Herz 26 (suppl 1): 2-8
58. O'Brien E. R., Garvin M. R., Dev R., Stewart D. K., Hinohara T, Simpson J. B. et al.. (1994) Angiogenesis in human coronary atherosclerotic plaques. Am. J. Pathol. 145: 883-894
59. McCarthy M. J., Loftus I. M., Thompson M. M., Jones L., London N. J., Bell P. R. et al. (1999) Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J. Vasc. Surg. 30: 261-268
60. De Meyer G. R., and Herman A. G. (1997) Vascular endothelial dysfunction. Prog. Cardiovasc. Dis. 39: 325-342
61. Cosentino F. and Luscher T. F. (1998) Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol. 32 (suppl 3): S54-S61
62. Yang Z., Kozai T., Loo B van der, Viswambharan H., Lachat M., Turina M. I. et al. (2000) HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll. Cardiol. 36: 1691-1697
63. Gonzalez-Fernandez F., Jimenez A., Lopez-Blaya A., Velasco S., Arriero M. M., Celdran A. et al. (2001) Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis 155: 61-70
64. Spyridopoulos I., Principe N., Krasinski K. L., Xu S., Kearney M., Magner M. et al. (1998) Restoration of E2F expression rescues vascular endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Circulation 98: 2883-2890
65. Laufs U., La F., V, Plutzky J. and Liao J. K. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135
66. Laufs U., Fata V. L. and Liao J. K. (1997) Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272: 31725-31729
67. Jimenez A., Arriero M. M., Lopez-Blaya A., Gonzalez-Fernandez F., Garcia R., Fortes J. et al. (2001) Regulation of endothelial nitric oxide synthase expression in the vascular wall and in mononuclear cells from hypercholesterolemic rabbits. Circulation 104: 1822-1830
68. Brovkovych V., Stolarczyk E., Oman J., Tomboulian P. and Malinski T. (1999) Direct electrochemical measurement of nitric oxide in vascular endothelium J. Pharm. Biomed. Anal. 19: 135-143
69. Gryglewski R. J., Palmer R. M. and Moncada S. (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454-456
70. Kalinowski L., Dobrucki L. W., Brovkovych V and Malinski T (2002) Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105: 933-938
71. Ni W, Egashira K, Kataoka C., Kitamoto S., Koyanagi M., Inoue S. et al. (2001)Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. 89: 415-421
72. Hernandez-Perera O., Perez-Sala D., Soria E. and Lamas S. (2000) Involvement of Rho GT Pases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ. Res. 87: 616-622
73. Wagner A. H., Kohler T., Ruckschloss U., Just I. and Hecker M. (2000) Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20: 61-69
74. Munzel T., Heitzer T. and Harrison D. G. (1997) The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 22: 158-172
75. Tsunekawa T., Hayashi T., Kano H., Sumi D., Matsui-Hirai H., Thakur N. K. et al. (2001) Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104: 376-379
76. Stein J. H., and Carlsson C. M. (2002) Cerivastatin and endothelial function in elderly patients with diabetes mellitus. Circulation 105: E32-E33
77. Hashimoto M., Akita H. (2002) Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 105: E30-E31
78. Sebestjen M., Zegura B. and Keber I. (2002) Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J. Intern. Med. 251: 77-85
79. Ziche M. and Morbidelli L. (2000) Nitric oxide and anglo-genesis. J. Neurooncol. 50: 139-148
80. Sata M., Nishimatsu H., Suzuki E., Sugiura S., Yoshizumi M., Ouchi Y. et al. (2001) Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 15: 2530-2532
81. Gibbons G. H. (1997) Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Clin. Cardiol. 20: II25
82. Nickenig G. and Harrison D. G. (2002) The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis. I. Oxidative stress and atherogenesis. Circulation 105: 393-396
83. Matsumoto K., Morishita R., Moriguchi A., Tomita N., Aoki M., Sakonjo H. et al. (2001) Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension 37: 270-274
84. Gryglewski R. J., Uracz W., Swies J., Chlopicki S., Marcinkiewicz E., Lomnicka M. et al. (2001) Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann. N. Y. Acad. Sci. 947: 229-245
85. Nickenig G., Baumer A. T., Temur Y., Kebben D., Jockenhovel F. and Bohm M. (1999) Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100: 2131-2134
86. Ichiki T., Takeda K., Tokunou T., Iino N., Egashira K., Shimokawa H. et al. (2001) Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21: 1896-1901
87. Dechend R., Fiebler A., Lindschau C., Bischoff H., Muller D., Park J. K. et al. (2001) Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am. J. Hypertens. 14: 55S-61S
88. Farmer J. A. and Torre-Amione G. (2002) Atherosclerosis and inflammation. Curr. Atheroscler. Rep. 4: 9-98
89. Takeuchi S., Kawashima S., Rikitake Y., Ueyama T., Inoue N., Hirata K. et al. (2000) Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun. 269: 97-102
90. Teupser D., Bruegel M., Stein O., Stein Y. and Thiery J. (2001) HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem. Biophys. Res. Commun. 289: 838-844
91. Viedt C., Hänsch G. M, Kübler W., Seeger F., Hanna K. and Kreuzer J. (2002) Die Komplement-vermittelte inflammatorische Aktivierung glatter Muskelzellen der Gefäßwand wird durch HMG-CoA Reduktase Hemmer verhindert. Z. Kardiol. 91 (suppl. 1): I/21
92. Viedt C., Hansch G. M., Brandes R. P., Kubler W. and Kreuzer J. (2000) The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. FASEB J. 14: 2370-2372
93. Horimoto H., Nakai Y., Nakahara K., Mieno S. and Sasaki S. (2001) HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals. J. Heart Lung Transplant. 20: 227
94. Ouchi K, Fujii B., Kudo S., Shirai M., Yamashita K., Gondo T. et al. (2000) Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic tissue. J. Infect. Dis. 181 (suppl 3): S441-S443
95. Kothe H., Dalhoff K., Rupp J., Muller A., Kreuzer J., Maass M. et al. (2000) Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101: 1760-1763
96. Garlichs C. D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M. et al. (2001) Upregulation of CD40 and CD40 ligand (CD 154) in patients with moderate hypercholesterolemia. Circulation 104: 2395-2400
97. Yoshida M., Sawada T., Ishii H., Gerszten R. E., Rosenzweig A., Gimbrone M. A. J. et al. (2001) HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 21: 1165-1171
98. Kaneider N. C., Reinisch C. M., Dunzendorfer S., Meierhofer C., Djanani A. and Wiedermann C. J. (2001) Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 158: 23-33
99. Puccetti L., Bruni F., Bova G., Cercignani M., Pompella G., Auteri A. et al. (2000) Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects: in vitro effect of cerivastatin. Int. J. Clin. Lab. Res. 30: 147-156
100. Edgington T. S., Mackman N., Brand K. and Ruf W. (1991) The structural biology of expression and function of tissue factor. Thromb. Haemost. 66: 67-79
101. Herkert O., Diebold I., Brandes R. P., Hess J., Busse R. and Gorlach A. (2002) NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 105: 2030-2036
102. Versteeg H. H., Hoedemaeker I., Diks S. H., Stam J. C., Spaargaren M., Bergen En Henegouwen P. M. van et al. (2000) Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J. Biol. Chem. 275: 28750-28756
103. Eto M., Kozai T., Cosentino F., Joch H. and Luscher T. F. (2002) Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105: 1756-1759
104. Lawler O. A., Miggin S. M. and Kinsella B. T. (2001) The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor. Br. J. Pharmacol. 132: 1639-1649
105. Berger J. and Moller D. E. (2002) The mechanisms of action of PPARS. Annu. Rev. Med. 53: 409-435
106. Inoue I., Goto S., Mizotani K., Awata T., Mastunaga T., Kawai S. et al. (2000) Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of RNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67: 863-876
107. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J. and Nakamura Y. (2001 ) Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 86: 3452-3456
108. Jiang C., Ting A. T. and Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
109. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M. et al. (2002) Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun. 290: 131-139
110. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J. C. et al. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107: 1423-1432
111. Robbie L. A., Booth N. A., Brown A. J. and Bennett B. (1996) Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 16: 539-545
112. Folsom A. R. (2001) Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb. Haemost. 86: 366-373
113. Isaacsohn J. L., Setaro J. F., Nicholas C., Davey J. A., Diotalevi L. J., Christianson D. S. et al. (1994) Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am. J. Cardiol. 74: 735-737
114. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K. and Wojta J. (2002) HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br. J. Pharmacol. 135: 284-292
115. Farmer J. A. (1998) Aggressive lipid therapy in the statin era. Prog. Cardiovasc. Dis. 41: 71-94
116. Kristensen S. D., Ravn H. B. and Falk E. (1997) Insights into the pathophysiology of unstable coronary artery disease. Am. J. Cardiol. 80: 5E-9E
117. Shiomi M., Ito T., Hirouchi Y. and Enomoto M. (2001) Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins. Ann. N. Y. Acad. Sci. 947: 419-423
118. Weissberg P. (1999) Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. Atherosclerosis 147 (suppl 1): S3-S10
119. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R. et al. (2001) Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89: 930-934
120. Clowes A. W. and Berceli S. A. (2000) Mechanisms of vascular atrophy and fibrous cap disruption. Ann. N. Y. Acad. Sci. 902: 153-161
121. Rosenson R. S. and Tangney C. C. (1998) Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279: 1643-1650
122. Forrester J. S. (2000) Role of plaque rupture in acute coronary syndromes. Am. J. Cardiol. 86: 15J-23J
123. Sotiriou C. G., Cheng J. W. (2000) Beneficial effects of statins in coronary artery disease - beyond lowering cholesterol. Ann. Pharmacother. 34: 1432-1439
124. Shiomi M. and Ito T. (1999) Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br. J. Pharmacol. 126: 961-968
125. Igarashi M., Takeda Y., Mori S., Ishibashi N., Komatsu E., Takahashi K. et al. (1997) Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol. 120: 1172-1178
126. Aikawa M., Rabkin E., Sugiyama S., Voglic S. J., Fukumoto Y., Furukawa Y. et al. (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103: 276-283
127. Ganne F., Vasse M., Beaudeux J. L., Peynet J., Francois A., Mishal Z. et al. (2000) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost. 84: 680-688
128. Kurata T., Kurata M. and Okada T. (2001 ) Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia. J. Int. Med. Res. 29: 329-334
129. Morishita R. (2001) Stabilization of plaque: the significance of vascular statins. Jpn. Med. J. 4002: C5-C8
130. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T. et al. (2001) Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 495: 159-166
131. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J. P. et al. (2002) Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol. 22: 623-629
132. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D. J. et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6: 1004-1010
133. Park H. J., Kong D., Iruela-Arispe L., Begley U., Tang D. and Galper J. B. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91: 143-150
134. Weis M., Heeschen C., Glassford A. J. and Cooke J. P. (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745
135. Roth D. R., Axel D. I. and Betz E. L. (1993) In vitro model of the inner parts of a vessel wall with cultured human vascular cells. Coron. Art. Dis. 4: 283-291
136. Axel D. I., Brehm B. R., Wolburg-Buchholz K., Betz E. L., Köveker G. and Karsch K. R. (1996)Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells. J. Vasc. Res. 33: 327-339
137. Axel D. I., Kunert W, Göggelmann C., Oberhoff M., Herdeg C., Küttner A. et al. (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96: 636-645
138. Axel D. I., Riessen R., Athanasiadis A., Runge H., Köveker G. and Karsch K. R. (1997) Growth factor expression of human arterial smooth muscle cells and endothelial cells in a transfilter coculture system. J. Mol. Cell. Cardiol. 29: 2967-2978
139. Axel D. I., Riessen R., Runge H., Viebahn R. and Karsch K. R. (2000) Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures in comparison to other statins. J. Cardiovasc. Pharmacol. 35: 619-629
140. Negrè-Aminou P., Vliet A. K. van, Erck M. van, Thiel C. F. van, Leeuwen R. E. W. van and Cohen L. H. (1997) Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys. Acta 1345: 259-268
141. Corsini A., Arnaboldi L., Raiteri M., Quarato P., Faggiotto A., Paoletti R. et al. (1996) Effect of the new HMG-CoA reductase inhibitor cerivastatin (Bay W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol. Res. 33: 55-61
142. Pentikainen P. J., Saraheimo M., Schwartz J. I., Amin R. D., Schwartz M. S., Brunner-Ferber F. et al. (1992) Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J. Clin. Pharmacol. 32: 136-142
143. Newby A. C. and George S. J. (1996) Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr. Opin. Cardiol. 11: 574-582
144. Raines E. W. (2000) The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int. J. Exp. Pathol. 81: 173-182
145. Riessen R., Axel D. I., Fenchel M., Herzog U. U., Rossmann H. and Karsch K. R. (1999) Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res. Cardiol. 94: 322-332
146. Patel M. K., Lymn J. S., Clunn G. F. and Hughes A. D. (1997) Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17: 2107-2114
147. Bornstein P. (2001) Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107: 929-934
148. Tulasne D., Judd B. A., Johansen M., Asazuma N., Best D., Brown E. J. et al. (2001) C-terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma-chain-associated signaling pathway and by agglutination. Blood 98: 3346-3352
149. Siegel-Axel D. I., Runge H., Seipel L. and Riessen R. (in press) Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and LDL levels. J. Cardiovasc. Pharmacol.
150. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G. et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949
151. Garrett I. R., Gutierrez G. and Mundy G. R. (2001) Statins and bone formation. Curr. Pharm. Des. 7: 715-736
152. Staa T. P. van, Wegman S., Vries F. de, Leufkens B. and Cooper C. (2001) Use of statins and risk of fractures. JAMA 285: 1850-1855
153. Wang P. S., Solomon D. H., Mogun H. and Avorn J. (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283: 3211-3216
154. Meier C. R., Schlienger R. G., Kraenzlin M. E., Schlegel B. and Jick H. (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283: 3205-3210
155. Bollen E. L., Gaw A. and Buckley B. M. (2001) Statin therapy and the prevention of dementia. Arch. Neurol. 58: 1023-1024
156. Cucchiara B. and Kasner S. E. (2001) Use of statins in CNS disorders. J. Neurol. Sci. 187: 81-89
157. Vaughan C. J., Delanty N. and Basson C. T. (2002) Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS Drugs 15: 589-596
158. Fassbender K., Simons M., Bergmann C., Stroick M, Lutjohann D., Keller P. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98: 5856-5861
159. Blais L., Desgagne A. and LeLorier J. (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. 160: 2363-2368
160. Pedersen T. R., Wilhelmsen L., Faergeman O., Strandberg T. E., Thorgeirsson G., Troedsson L. et al. (2000) Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol. 86: 257-262
161. Elson C. E., Peffley D. M., Hentosh P. and Mo H. (1999) Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med. 221: 294-311
162. Wong W. W., Tan M. M., Xia Z., Dimitroulakos J., Minden M. D. and Penn L. Z. (2001) Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res. 7: 2067-2075
163. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K, Tiemann M. et al. (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108: 391-397
164. Aßmus B., Zeiher A. M. and Dimmeler S. (2002) Atorvastatin hemmt die Seneszenz von humanen endothelialen Progenitorzellen. Z. Kardiol. 91 (suppl. 1): I/75
165. Heeschen C., Johnson F., Pathak A., Quertermous T. and Cooke J. P. (2002) Mobilization of endothelial progenitor cells during ischemia. Z. Kardiol. 91 (suppl. 1): I/116
166. Furberg C. D. and Pitt B. (2002) Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2: 205-207